11. Segment Information Segment Reporting

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

SEGMENT INFORMATION

Information regarding industry segments for the three months ended March 31, 2020 and 2019 is as follows (in millions):

		Life Science		Clinical Diagnostics		Other Operations
Segment net sales	2020	$	227.2	$	340.3	$	4.1
	2019	$	215.7	$	334.1	$	4.2
Segment net profit (loss)	2020	$	25.4	$	46.2	$	0.7
	2019	$	22.8	$	30.9	$	(0.1	)

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance.  Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker.  Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. For the three months ended March 31, 2020 compared to the same period in 2019, our Life Science segment had increased sales, partially offset by increased cost of goods sold, while our Clinical Diagnostics segment had increased sales, along with decreased selling, general and administrative expense. The following reconciles total segment profit to consolidated income before income taxes (in millions):

	Three Months Ended
	March 31,
	2020			2019
Total segment profit	$	72.3		$	53.6
Foreign currency exchange losses, net	(0.9		)	(1.3		)
Net corporate operating, interest and other expense not allocated to segments	(3.7		)	(2.9		)
Change in fair market value of equity securities	827.7			1,059.2
Other income (expense), net	3.3			18.7
Consolidated income before income taxes	$	898.7		$	1,127.3